Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA...
Day: September 29, 2023
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted...
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric...
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
VantAI Announces Formation of Scientific Advisory Board
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- VantAI, a leading company focused on the application of artificial intelligence to...
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial...
Dentsply Sirona Announces Planned Board Succession
CHARLOTTE, N.C., Sept. 29, 2023 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that,...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
Capricor Therapeutics Announces $23 Million Registered Direct Offering
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds,...
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight...
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
Stephen Dilly Headshot Stephen Dilly, MBBS, PhD, President & CEO of Codexis, Inc.REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE)...
Microbix Presenting at Muskoka Capital Conference
Meetings with Growth-Oriented Investors, September 29 to October 1, 2023MISSISSAUGA, Ontario, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc....
‘Potently Canadian’ Cannabis Brand, CANACA, Launches ‘Let ‘Er Rip’ Campaign
CANACA Introduces New Flower Offerings and Infused Pre-roll LineupTORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or...
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation...
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential...
AMBU FINANCIAL CALENDAR FOR 2023/24
This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as...
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and...